Skip to Content

Handa Pharmaceuticals Inc 6620

Morningstar Rating
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

6620 is trading at a 770% premium.
Price
TWD 137.97
Fair Value
TWD 961.33
Uncertainty
Very High
1-Star Price
TWD 994.42
5-Star Price
TWD 84.44
Economic Moat
Jyzl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 6620 is a good fit for your portfolio.

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
25.62
Price/Sales
16.91
Dividend Yield (Trailing)
0.72%
Dividend Yield (Forward)
0.72%
Total Yield
0.72%

Company Profile

Handa Pharmaceuticals Inc is a Taiwan based specialty pharmaceutical company. It is engaged in the development of niche drug. The company focuses on the development of high barrier/patentable niche products.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
13

Comparables

Valuation

Metric
6620
1701
4132
Price/Earnings (Normalized)
25.6220.34
Price/Book Value
7.120.899.44
Price/Sales
16.910.7859.93
Price/Cash Flow
23.6011.96
Price/Earnings
6620
1701
4132

Financial Strength

Metric
6620
1701
4132
Quick Ratio
12.900.870.75
Current Ratio
12.961.651.14
Interest Coverage
3,488.967.38−53.99
Quick Ratio
6620
1701
4132

Profitability

Metric
6620
1701
4132
Return on Assets (Normalized)
36.62%2.57%−39.36%
Return on Equity (Normalized)
39.46%4.40%−60.61%
Return on Invested Capital (Normalized)
38.19%3.43%−41.37%
Return on Assets
6620
1701
4132
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AXvjyptwqkXky$77.1 Bil
MKKGY
Merck KGaA ADRTftclbbltWhbknn$72.9 Bil
HLN
Haleon PLC ADRCqvbvmkKmnlr$37.5 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRFpgrmylWghs$18.3 Bil
VTRS
Viatris IncBxlzdwxhcKdtbg$13.3 Bil
RDY
Dr Reddy's Laboratories Ltd ADRPcybssqQnw$11.7 Bil
CTLT
Catalent IncFwgwfxkXknhh$10.1 Bil
PRGO
Perrigo Co PLCRskfxfgyNtsq$4.2 Bil
CURLF
Curaleaf Holdings IncVqjbwkwpMns$4.1 Bil
PBH
Prestige Consumer Healthcare IncMtlmwtmkKtgtj$3.5 Bil

Sponsor Center